<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581878</url>
  </required_header>
  <id_info>
    <org_study_id>17845</org_study_id>
    <secondary_id>2014-004140-36</secondary_id>
    <nct_id>NCT02581878</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish a recommended dose of BAY1862864 Injection and to investigate how the study drug&#xD;
      acts in the body, on the cancer cells and how safe it is in patients with advanced&#xD;
      non-Hodgkin's lymphoma (NHL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided into two parts: a &quot;dose-escalation part&quot; to evaluate safety profile&#xD;
      and to explore the Maximum tolerated dose (MTD) and an &quot;expansion part&quot; to evaluate further&#xD;
      the safety and tumor response profile of BAY1862864 Injection at the selected dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Actual">November 26, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose assessed by the number of subjects with dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1862864</intervention_name>
    <description>Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has relapsed or refractory CD22-positive histologically confirmed NHL&#xD;
&#xD;
          -  An archival paraffin-embedded tissue or fresh biopsy is available for the&#xD;
             retrospective quantitative assessment of CD22 levels&#xD;
&#xD;
          -  Bone marrow involvement of cellular marrow with lymphoma determined to be &lt; 25%&#xD;
&#xD;
          -  Subject has failed at least one prior chemo-/immunotherapy-based regimen&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Not eligible for, or refused, or failed high-dose therapy combined with autologous&#xD;
             stem cell rescue (HDT ASCR)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2&#xD;
&#xD;
          -  Women of childbearing potential must have negative pregnancy test within seven days&#xD;
             before the start of treatment&#xD;
&#xD;
          -  Subject was using adequate barrier birth control measures before the study and is&#xD;
             willing to continue use of these during the entire course of the study and for the&#xD;
             twelve months after the last administration of BAY1862864 Injection&#xD;
&#xD;
          -  Adequate bone-marrow, hepatic and renal function&#xD;
&#xD;
          -  Subject is capable of giving informed consent and has provided such consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to the study drug. Previous exposure to CD22 antibody within six&#xD;
             months before screening. Any radio-immunotherapy within six months before screening.&#xD;
&#xD;
          -  History of anaphylactic reactions to monoclonal antibody therapy. Known or suspected&#xD;
             allergy or intolerance to any agent to be given in the course of this study.&#xD;
&#xD;
          -  Anti-cancer immunotherapy and/or anti cancer chemotherapy within four weeks before the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Previous therapy with fludarabine-containing regimens within three months before&#xD;
             screening&#xD;
&#xD;
          -  Participation in any other clinical trial in which the subject received active therapy&#xD;
             within four weeks before the first scheduled dose of study drug&#xD;
&#xD;
          -  Any toxic effects (CTCAE ≥ Grade 2) of previous anti cancer therapy (incl.&#xD;
             radiotherapy) that have not yet stabilized or significant post-treatment toxicities&#xD;
             have been observed&#xD;
&#xD;
          -  Prior definitive radiotherapy completed less than four weeks before the date scheduled&#xD;
             for first dose of BAY1862864&#xD;
&#xD;
          -  History of symptomatic metastatic brain or meningeal tumors. Presence of new or&#xD;
             progressive brain metastases.&#xD;
&#xD;
          -  History of clinically significant cardiac disease&#xD;
&#xD;
          -  Clinically relevant findings in the ECG.&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as systolic blood pressure &gt; 160 mmHg and / or&#xD;
             diastolic blood pressure &gt; 100 mmHg, despite optimum medical management&#xD;
&#xD;
          -  History of arterial or venous thrombotic or embolic events, such as cerebrovascular&#xD;
             accident (including transient ischemic attack), deep vein thrombosis, or clinically&#xD;
             relevant pulmonary embolism within three months before the first administration of&#xD;
             BAY1862864 (except for adequately treated catheter-related venous thrombosis occurring&#xD;
             more than one month before start of study medication)&#xD;
&#xD;
          -  Autologous bone-marrow transplant or stem-cell rescue within three months before the&#xD;
             first administration of BAY1862864&#xD;
&#xD;
          -  Organ allograft (except for corneal transplant) or allogeneic bone-marrow transplant&#xD;
             at any time before the first administration of BAY1862864&#xD;
&#xD;
          -  Positive result of hepatitis B virus (HBV-DNA) and/or human immunodeficiency virus&#xD;
             antibody (HIV-Ab) test&#xD;
&#xD;
          -  Liver cirrhosis, defined as Child-Pugh class B or C&#xD;
&#xD;
          -  Any active infection of CTCAE Grade ≥2&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study&#xD;
&#xD;
          -  Major surgery or significant trauma within four weeks before the first administration&#xD;
             of BAY1862864&#xD;
&#xD;
          -  Any treatment with biological response modifiers (such as, but not limited to,&#xD;
             granulocyte colony-stimulating factor, G CSF), or any blood transfusion, within three&#xD;
             weeks before first administration of BAY1862864&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study result&#xD;
&#xD;
          -  Current pregnancy or breast-feeding&#xD;
&#xD;
          -  Any condition that is unstable or could jeopardize the safety of the subject and&#xD;
             his/her compliance with study requirements&#xD;
&#xD;
          -  Close affiliation with the investigation site&#xD;
&#xD;
          -  Any use by the subject of illicit drugs or other substances that may, in the opinion&#xD;
             of the investigator or his/her designated associate(s), have a reasonable chance of&#xD;
             contributing to toxicity or otherwise confound the results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thorium-227</keyword>
  <keyword>BAY1862864 Injection</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>CD22</keyword>
  <keyword>Radioimmunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

